• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Progenics Pharmaceuticals, Inc. (PGNX)

    -NasdaqGS
    6.51 Down 0.12(1.81%) Feb 27, 4:00PM EST
    |After Hours : 6.52 Up 0.01 (0.08%) Feb 27, 4:32PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingSep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013
    Total Revenue 41,656   1,477   1,815   2,968  
    Cost of Revenue10  180  90  253  
    Gross Profit 41,646   1,297   1,725   2,715  
    Operating Expenses
    Research Development6,728  7,833  6,934  7,698  
    Selling General and Administrative(2,855)4,271  3,890  3,459  
    Non Recurring895  147  82  316  
    Others142  133  144  165  
    Total Operating Expenses4,910  12,384  11,050  11,638  
    Operating Income or Loss 36,736   (11,087) (9,325) (8,923)
    Income from Continuing Operations
    Total Other Income/Expenses Net12  13  12  10  
    Earnings Before Interest And Taxes36,748  (11,074)(9,313)(8,913)
    Interest Expense -   -   -   -  
    Income Before Tax36,748  (11,074)(9,313)(8,913)
    Income Tax Expense(227)(1) -  (362)
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops36,975  (11,073)(9,313)(8,551)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income 36,975   (11,073) (9,313) (8,551)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares 36,975   (11,073) (9,313) (8,551)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.